APICA

APICA is a synthetic cannabinoid that has been identified in illegal products sold as "herbal spice" or "synthetic cannabis". It is a potent agonist for the CB1 receptor, with a Ki of 2.2 nM, and the CB2 receptor, with a Ki of 1.0 nM. APICA was first identified in South Korea in 2012.

Chemistry

APICA, also known as 2NE1 and SDB-001, is a synthetic cannabinoid that is structurally related to AM-2201, a potent synthetic cannabinoid that is often found in synthetic cannabis blends. APICA is an indole-based synthetic cannabinoid, with the indole group attached to the aminoalkylindazole group at the 1-position. The structure of APICA includes a naphthyl group, which is substituted at the 1-position of the indole core, and a carboxamide group, which is attached to the 3-position of the indole core.

Pharmacology

APICA acts as a potent agonist for the CB1 receptor, which is primarily located in the brain and is responsible for the psychoactive effects of cannabis. It has a Ki of 2.2 nM for the CB1 receptor, making it more potent than many other synthetic cannabinoids. APICA also acts as an agonist for the CB2 receptor, which is primarily located in the immune system. It has a Ki of 1.0 nM for the CB2 receptor.

Legal status

APICA is illegal in many countries, including the United States, where it is a Schedule I controlled substance. It is also illegal in the United Kingdom, where it is a Class B drug under the Misuse of Drugs Act 1971.

See also

• Synthetic cannabinoids
• Cannabinoid receptor
• AM-2201

APICA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia